Antiplatelet therapy plays a major role in the management of unstable angina/NSTEMI. This class of medication is directed towards one of the following three pathways: decreasing thromboxane A2 formation<unk> , inhibiting the P2Y12 component of the adenosine diphosphate (ADP) receptor pathway (thienopyridines) and direct inhibition of platelet aggregation (GP IIb/IIIa inhibitors).
Unstable angina / non ST elevation myocardial infarction aspirin therapy
Unstable angina / non ST elevation myocardial infarction nitrate therapy
ST elevation myocardial infarction anticoagulant and antithrombotic therapy
ST elevation myocardial infarction primary percutaneous coronary intervention
Chronic stable angina treatment calcium channel blockers
Unstable angina / non ST elevation myocardial infarction coronary angiography
Chronic stable angina cardiac magnetic resonance imaging
Unstable angina / non ST elevation myocardial infarction low molecular weight heparin therapy